2007/9-至今，山东大学，药学院，教授 2004/12-2007/9，山东大学，药学院，副教授 2002/9-2004/12，美国北卡罗莱纳州立大学、佐治亚州立大学化学系博士后 2001/9-2002/8，美国密歇根大学药学院博士后 1996/9-2001/6，中国药科大学药物化学专业，博士研究生 1992/9-1996/6，中国药科大学化学制药专业，本科

1.基于靶点结构的创新药物研究：主要针对恶性肿瘤和自身免疫性疾病等相关药物靶标，基于药物靶标结构和计算化学原理，开展分子设计、类药化合物合成及生物活性评价等方面的创新药物研究。 2.化学生物学：研究小分子化合物调控细胞凋亡及表观遗传等方面功能

Chen C, Li X, Zhao H, Liu M, Du J, Zhang J, Yang X, Hou X*,Fang H*. Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.J. Med. Chem.2022, 65(4):3667-3683. Liu M, Gao S, Liang T, Qiu X, Yang X,Fang H*, Hou X*. Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.J. Med. Chem.2022, 65(18):12200-12218. Liu M, Gao S, Elhassan RM, Hou X*,Fang H*. Strategies to overcome drug resistance using SHP2 inhibitors.Acta Pharm. Sin. B.2021,11(12):3908-3924. Elhassan RM, Hou X*,Fang H*. Recent advances in the development of allosteric protein tyrosine phosphatase inhibitors for drug discovery.Med. Res. Rev.2022, 42(3):1064-1110. Liang T, Zhou Y, Elhassan RM, Hou X, Yang X,Fang H*. HDAC-Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells.J. Med. Chem., 2020, 63(20):12083-12099. Zhou Y, Liu X, Xue J, Liu L, Liang T, Li W, Yang X, Hou X,Fang H*. Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.J. Med. Chem.,2020, 63, 4701-4715. Liang T, Xue J, Yao Z, Ye Y, Yang X, Hou X, Fang H. Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.Eur. J. Med. Chem., 2021, 221, 113526. Hou X, Sun J-P, Ge L, Liang X, Li K, Zhang Y,Fang H*. Inhibition of Striatal-enriched Protein Tyrosine Phosphatase by Targeting Computationally Revealed Cryptic Pockets.Eur. J. Med. Chem.,2020, 190, 112131. Liu L, Liu R, Yang X, Hou X*,Fang H*. Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors.Eur. J. Med. Chem.2020, 191, 112142. Liang T, Hou X, Zhou Y, Yang X,Fang H*. Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.ACS Med. Chem. Lett.2019, 10, 1122-1127. Chen C, Yang X,Fang H*, Hou X*. Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors.Eur. J. Med. Chem.,2020, 181, 111563. Hou X, Rooklin D, Yang D, Liang X, Li K, Lu J, Wang C, Xiao P, Zhang Y, Sun J,Fang H*. Computational Strategy for Bound State Structure Prediction in Structure-Based Virtual Screening: A Case Study of Protein Tyrosine Phosphatase Receptor Type O Inhibitor.J. Chem. Inf. Model.,2018, 58, 2331-2342. Xu Y, Yang X,Fang H*. Additive-and Photocatalyst-Free Borylation of Arylazo Sulfones under Visible Light.J. Org. Chem.,2018, 83, 12831-12837. Chen C, Hou X, Wang G, Pan W, Yang X, Zhang Y,Fang H*. Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.Eur. J. Med. Chem.,2017, 133, 11-23. Hou X, Li R, Li K, Yu X, Sun J,Fang H*. Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening.J. Med. Chem.2014, 57, 9309-9322.